Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
The World Health Organisation says using plasma by the recovered to treat COVID-19 is still considered an”experimental” therapy and that the preliminary results demonstrating it may function are still”inconclusive.”
President Donald Trump on Sunday accepted an emergency authorisation of convalescent plasma for COVID-19 patients.
WHO’s chief scientist Dr Soumya Swaminathan said convalescent plasma therapy was used in the last century to treat several infectious diseases, with varying levels of success.
Swaminathan says WHO still believes convalescent plasma therapy to be experimental and said it should continue to be evaluated.
She added that the treatment is hard to standardise, because people create various levels of antibodies as well as the plasma has to be collected individually from recovered patients.
Swaminathan says the studies have been provided and small”low-quality evidence.”
She says countries can”do a crisis list should they think the advantages outweigh the dangers” but that’s”usually done when you are waiting for the more definitive evidence.”
Dr Bruce Aylward, a senior advisor to WHO’s director-general, said that convalescent plasma therapy can come with numerous side effects, in the mild fever and chills to more severe lung-related injuries.
